On April 22, 2026, the Drug Enforcement Administration issued a final order moving specific marijuana products from Schedule I to Schedule III of the Controlled Substances Act - and the downstream effects on federal tax law are immediate, technical, and uneven. For state-licensed medical marijuana operators, the order ends years of punishing tax treatment under I.R.C. § 280E. For everyone else in the cannabis industry, nothing has changed.
How § 280E Has Functioned as a Slow Tax on Cannabis Operators
To understand what this rescheduling actually changes, it helps to understand what § 280E actually does - and how blunt an instrument it is. The provision bars any trade or business from claiming standard deductions or credits if that business consists of trafficking in Schedule I or II controlled substances in violation of federal or state law. No rent deductions. No payroll deductions. No ordinary business expenses whatsoever. Operators could only reduce taxable income through cost of goods sold, a narrow accounting measure that excludes most of what it actually costs to run a company.
Congress originally wrote § 280E in 1982 in response to a Tax Court decision allowing a cocaine dealer to deduct business expenses - the legislative logic being that no one should profit, tax-advantaged, from drug trafficking. What legislators did not anticipate was that state-legal medical dispensaries operating openly, paying taxes, and employing licensed staff would eventually be caught in the same provision. The result, in practice, has been effective tax rates that frequently exceeded 70 percent for cannabis businesses, because gross revenue was taxed with almost no corresponding expense recognition. That is not a rounding error. It has forced some legitimate operators into insolvency.
What the Final Order Actually Says - and What It Doesn't
The DEA's order places into Schedule III "marijuana as defined in the CSA... to the extent that any of these are included in an FDA-approved drug product or are subject to a state-issued license to manufacture, distribute, and/or dispense marijuana or products containing marijuana for medical purposes." That language is doing enormous legal work. It is not a blanket reclassification of cannabis. It is a conditional one, scoped tightly to two categories: FDA-approved products (currently, that means Epidiolex and its analogs) and state-licensed medical marijuana operations.
The order is explicit on the § 280E consequence: "state licensees will no longer be subject to the deduction disallowance imposed by Section 280E of the Internal Revenue Code, which applies only to businesses engaged in 'trafficking in controlled substances . . . in a schedule I or II.'" The DEA Administrator also encouraged the Treasury Secretary to consider retrospective relief - meaning potential refunds or amended-return opportunities for prior tax years. That's a meaningful acknowledgment. Whether Treasury acts on it is a separate question entirely, and practitioners should not advise clients to act on that possibility without formal IRS guidance in hand.
Here's the catch for everyone outside that perimeter: recreational marijuana, adult-use dispensaries, and any state-legal cannabis business operating without a medical license retains its Schedule I classification. The § 280E bar is fully intact. Those operators still cannot deduct rent, wages, or utilities. The final order does not gesture toward future reclassification of recreational marijuana, and the DOJ includes a standard disclaimer that nothing in the rule constitutes a tax determination - a reminder that tax counsel, not regulatory text, should drive specific filing decisions.
A New Path Opens for Medical Deductions Under § 213 - With Conditions
For individual taxpayers, the rescheduling opens a separate door that has been firmly closed since at least 1997, when the IRS issued Rev. Rul. 97-9. That ruling denied all § 213 deductions for marijuana - even physician-recommended purchases in states where medical use was legal - on the grounds that federal Schedule I status made possession a federal offense, and therefore the expenditure was not "legally procured" as required under Treas. Reg. § 1.213-1(e)(2).
The legal foundation of that ruling has now eroded. State-licensed medical marijuana sitting in Schedule III has a federally recognized medical use; authorized possession no longer violates the CSA. The "legally procured" hurdle, which was § 213's primary bar for cannabis, is effectively cleared - at least for Schedule III-qualifying products obtained through a state medical program. Rev. Rul. 97-9 has not been formally revoked, but its operative premise no longer holds for this category of product.
What remains is the prescription requirement. I.R.C. § 213(d)(3) limits the deduction to drugs obtained pursuant to a physician's prescription, and that definition is strict at the federal level. A physician's recommendation or a state-issued medical marijuana card may or may not satisfy it, depending on documentation and the specific structure of a state's licensing framework. Practitioners advising clients on Schedule A deductions need to scrutinize whether the patient's paperwork - the actual clinical documentation, not just the dispensary receipt - meets the federal prescription standard. If it does, the expense can be deducted to the extent total medical costs exceed 7.5 percent of adjusted gross income, the standard § 213(a) threshold.
For recreational users who self-medicate without a prescription: non-deductible, full stop. Two independent bars apply simultaneously. Adult-use marijuana remains Schedule I, so Rev. Rul. 97-9 still governs. And even if that weren't true, § 213(b) requires a prescribed drug - a category recreational marijuana categorically fails to enter, regardless of how it's used.
Practical Implications for Tax Practitioners
The immediate advisory priority is segmentation. Cannabis clients operating across both medical and adult-use lines - and many multi-state operators do - need to ensure their entity structures, accounting systems, and revenue recognition cleanly separate the two activities. Commingled operations could expose the § 280E-exempt medical business to the taint of the recreational side, a risk that is not hypothetical. The IRS has historically scrutinized cannabis businesses with unusual care, and the bifurcated post-rescheduling framework will not reduce that scrutiny.
For individual clients, the path to a § 213 deduction is plausible but not automatic. The sequence matters: Schedule III classification, state medical license program, physician prescription meeting the federal definition, and total medical expenses clearing the AGI threshold. Practitioners who move too quickly - treating the rescheduling as a clean green light without walking through each requirement - are running ahead of the available guidance.
The DEA's April 2026 order represents the most significant structural change to cannabis taxation since § 280E was first applied to state-legal businesses. It is also, notably, a half-measure. Medical operators get relief. Recreational operators do not. And between those two categories sits a federal tax code that will now require practitioners to draw distinctions that, until last month, simply did not exist in this space.
